MIRA Pharmaceuticals reports positive toxicology results for MIRA-55; targets Q1 2027 IND

MIRA PHARMACEUTICALS, INC.

7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs completed with positive results.
Rats identified as more sensitive species; dogs showed greater tolerance; systemic exposure confirmed in both.
Results inform dose selection for next phase of IND-enabling program; GLP-compliant studies planned.
Company targets IND submission to FDA for MIRA-55 in Q1 2027, subject to remaining studies.
MIRA-55 is an oral non-opioid candidate for inflammatory pain; DEA has determined it is not a controlled substance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.